Download Files:
Products Details
Product Description
– Daunorubicin (Daunomycin) citrate is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin citrate inhibits DNA and RNA synthesis. Daunorubicin citrate is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin citrate is also an anthracycline antibiotic. Daunorubicin citrate can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing’s sarcoma, Wilms’ tumor[1][2][4][5].
Web ID
– HY-108876
Shipping
– Room temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C33H37NO17
References
– [1]Lehmann M, et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ Mol Mutagen. 2004;43(4):250-7. |[2]Dano K, et al. Inhibition of DNA and RNA synthesis by daunorubicin in sensitive and resistant Ehrlich ascites tumor cells in vitro. Cancer Res. 1972 Jun;32(6):1307-14. |[3]Svensson SP, et al. Melanin inhibits cytotoxic effects of Doxorubicin and Daunorubicin in MOLT 4 cells. Pigment Cell Res. 2003 Aug;16(4):351-4. |[4]Gervasoni JE Jr, et al. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and Daunorubicin by induction of both necrosis and apoptosis. Anticancer Res. 2004 Sep-Oct;24(5A):2617-26. h|[5]Arozal W, et al. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions. Toxicology. 2011 Jan 11;279(1-3):91-9. |[6]Emeline Bollaert, et al. MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin. Int J Mol Sci. 2021 May 13;22(10):5153. |[7]Cheng Wu, et al. Doxorubicin suppresses chondrocyte differentiation by stimulating ROS production. Eur J Pharm Sci. 2021 Dec 1;167:106013.
CAS Number
– 1884557-85-0
Molecular Weight
– 719.64
SMILES
– OC(C(O)=O)(CC(O)=O)CC(O)=O.OC1=C2C([C@H](C[C@@](C(C)=O)(O)C2)O[C@@]3([H])C[C@@H]([C@H](O)[C@H](C)O3)N)=C(O)C4=C1C(C5=CC=CC(OC)=C5C4=O)=O
Clinical Information
– Launched
Research Area
– Cancer; Infection; Neurological Disease
Solubility
– 10 mM in DMSO
Target
– ADC Cytotoxin;Antibiotic;Apoptosis;Autophagy;Bacterial;DNA/RNA Synthesis;Topoisomerase
Isoform
– Daunorubicins/Doxorubicins;Topo II
Pathway
– Antibody-drug Conjugate/ADC Related;Anti-infection;Apoptosis;Autophagy;Cell Cycle/DNA Damage
Product type
– ADC Related
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
Related Products
1000 in stock
